S. Banerjee

发表

Hemorrhagic dot score as a follow up marker in psoriasis on treatment: A prospective observational study

S. Arora, D. Paul, S. Banerjee, 2022, Dermatologic therapy.

Abatacept in the Treatment of Active Psoriatic Arthritis : 24-Week Results from a Phase III Study

A. Gottlieb, D. Gladman, P. Mease, 2017 .

Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate‐to‐severe plaque psoriasis

J. Erickson, D. Shrom, W. Shen, 2013, The British journal of dermatology.

Lack of a Clinically Relevant Effect of an Antacid on the Pharmacokinetics of Lersivirine

R. Labadie, M. Vourvahis, H. Mayer, 2010, Antimicrobial Agents and Chemotherapy.

LB0004 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYK2 INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

J. Merrill, M. Pike, E. Morand, 2022, Annals of the Rheumatic Diseases.

POS1046 DEUCRAVACITINIB LONG-TERM EFFICACY AND SAFETY IN PLAQUE PSORIASIS: 2-YEAR RESULTS FROM THE PHASE 3 POETYK PSO PROGRAM

A. Blauvelt, A. Menter, H. Sofen, 2022, Annals of the Rheumatic Diseases.

THU0104 Both MRI and HAQ-DI can predict relapses following all treatment withdrawal in MTX-NAÏVE patients with RA in remission after 12 months of abatacept therapy in the avert trial

P. Conaghan, M. Østergaard, H. Ahmad, 2017 .

FRI0227 Five-Year Safety and Efficacy of Subcutaneous Abatacept in Patients with Moderate To Severely Active RA and An Inadequate Response To MTX: Long-Term Extension of The Phase III, Double-Blind, Randomized Acquire Study

E. Nasonov, P. Durez, P. Nash, 2016 .

Treating adult patients of severe psoriasis with methotrexate leads to reduction in biomarkers of atherosclerosis: A prospective study

Roma Rai, B. Vasudevan, S. Neema, 2023, Medical Journal Armed Forces India.

A high level of clinical response is associated with improved patient‐reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab

W. Shen, E. Edson-Heredia, K. Gordon, 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

OP0021 A phase 2 study of multiple subcutaneous doses of LY2439821, an anti-IL-17 monoclonal antibody, in patients with rheumatoid arthritis in two populations: Naïve to biologic therapy or inadequate responders to tumor necrosis factor alpha inhibitors

M. Genovese, D. Braun, G. Cameron, 2013 .

OP0215 Subcutaneous Abatacept in Patients with Polyarticular Juvenile Idiopathic Arthritis and Inadequate Response To Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Pharmacokinetics, Efficacy and Safety

A. Martini, A. Berman, J. Antón, 2016 .

POS0005 BASELINE BIOMARKERS PREDICT BETTER RESPONSES TO DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, IN A PHASE 2 TRIAL IN PSORIATIC ARTHRITIS

D. Gladman, O. FitzGerald, J. Smolen, 2022, Annals of the Rheumatic Diseases.

Lack of a Clinically Relevant Effect of an Antacid on the Pharmacokinetics of Lersivirine

M. Vourvahis, H. Mayer, S. Banerjee, 2010, Antimicrobial Agents and Chemotherapy.